Northwest Bioth Cmn (NWBO)

$NWBO the fact approval for DCVax-L is still pending and no rejection has been received is a great sign IMO. If you don’t believe me, just look at all the random shorts showing up to trash old, disproven theories. It’s the same old regurgitated, baseless FUD that holds zero weight. How many negative PRs have you recieved from management in the last few years? Everything is moving forward as expected, albeit more slowly than many anticipated. This doesn’t change what’s ahead for investors…. I see so many green lights that my vision gets blurry at times, and I pause to analyze further and reevaluate my sentiment. However, I can still not see this as anything but a positive trajectory. I will continue accumulating… this is a top notch management team that’s genuinely trying to save lives. Not a pump and dump… but once the wins are followed by pumps, they will be far more meaningful.

$NWBO acquired Advent BioServices to bring its key manufacturing partner in house, aiming to integrate operations, enhance efficiency, reduce costs, gain control over manufacturing facilities and equipment, and simplify the path to market for its DCVax-L personalized cancer vaccine. Bringing manufacturing in-house through the acquisition is expected to lower costs and prepare the company for substantial scale-up of operations. Regulatory and Commercial Benefits: Advent's MHRA-licensed facilities support global distribution and are essential for advancing the DCVax-L approval and DCVax-Direct development programs. Reduced Dilution: The acquisition involves the recovery of 19 million NWBO securities (shares and options) that were previously issued to Advent, which helps to reduce future dilution for existing shareholders. NWBO views Advent as a template for a global strategy of acquiring integrated regional nodes, allowing the company to replicate its success in other continents.

$NWBO Just putting it out there... I say f Merck and go with whoever is the highest bidder on the defensive move. Pfizer, Bristol, what's your highest bid? Want to gamble that enhanced dendritic cell immunotherapy and checkpoint inhibitor trials don't work on other cancers? Who can shepherd DCVAX Direct through approvals the quickest? Want to compete with Keytruda? And wait... who's got manufacturing already built and owned, approved by the UK, and already patented? Along with the combo patent? Along with settlements that could reach $1-2 billion in a year. I want to see numbers above $20/share... or go back and get your calculators out... ;o)

$NWBO I tried to post a message 3 times, but it only shows up on my profile page. I don't know if anyone else can see it. If someone sees it on my profile page, please let me know. Good luck to all longs.

$NWBO adding another 25K+ shares in the next couple of weeks. Will add nicely to my over 291K portfolio.

$NWBO Is it fair to say that Advent bioservices mainly provides manufacturing on DCVax-L? Can we assume the revenue from the Specials program is being used for the development and expansion of the company?

$NWBO outstanding shares not being exercised means no one wants to exercise them , not good news.

$NWBO @broken_zamboni @Makeitcometrue @RRCORNER and my other troll jesters… I’m adding another 1500 shares early next week so you or your bosses lose more $$$ when approved!!! Have a great remaining weekend to you three

$NWBO Does NWBO not get revenue from compassionate use?

$NWBO what brokers carry it?

$NWBO Have a great weekend Longs.

$NWBO SHARES OUTSTANDING HAVE NOT BUDGED FOR A WEEK! This means; 1. THEY ARE NOT DILUTING 2. WARRANT HOLDERS AREN’T EXERCISING THEIR WARRANTS. #2 is FAR MORE SIGNIFICANT because we know from SEC FILINGS that there’s hundreds of millions of those warrants sitting out there, the excercise of which would bring in much-needed cash. The company is DELIBERATELY BLOCKING WARRANT EXERCISES right now, probably to avoid diluting the stock just before what looks like an upcoming MHRA approval or maybe a partnership deal. Basically, THEY WANT TO KEEP THINGS NEAT AND PROTECT THE SHARE PRICE AHEAD OF BIG NEWS and/or THEY NEED A “CLEAN CAP” in order to finalize some transaction. If LP really has been planning the ultimate short squeeze, this would have been the plan all along. By PUTTING A HOLD ON WARRANT EXERCISES NOW, they might be betting on raising money at a MUCH HIGHER VALUATIONS or VIA A PARTNERSHIP ANNOUNCEMENT. The ADVENT PR and LL CONFERENCES also fit nicely with this pause.

$NWBO nbyb in Germany

$NWBO https://x.com/Richard67637214/status/1974139527838249138

$NWBO what is the German ticker?

$NWBO @RODDAVIDSON HE (I MEAN THEY) WORKS NIGHTS AND WEEKENDS AND ALWAYS DELIVERS THAT FUD 24/7/365! HE (I MEAN THEY) IS KIND OF LIKE AN EVIL POSTMAN (I MEAN POSTMEN, PLURAL). SERIOUSLY THOUGH I AN STARTING TO GET EXCITED THAT THEIR BOSSES ARE ABOUT TO GET ABSOLUTELY WRECKED!

$NWBO d_stock @d_stock07734 · 39m $NWBO @TigonTalker It's fascinating to see all those DC vaccine trials conducted at different prestigious institutions which may share something in common. Some longs think that $NWBO is a start-up company. It's not. It's a giant currently invisible to most people! Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer https://clinicaltrials.gov/study/NCT01312376 Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer https://pmc.ncbi.nlm.nih.gov/articles/PMC3583933/ Lana E Kandalaft , Daniel J Powell Jr, Cheryl L Chiang, Janos Tanyi, Sarah Kim, Marnix Bosch, Kathy Montone, Rosemarie Mick, Bruce L Levine, Drew A Torigian, Carl H June, George Coukos https://cancerresearch.org/blog/barbara-l Barbara was treated at the Abramson Cancer Center at University of Pennsylvania by George Coukos, MD, PhD, and Janos Tanyi, MD, PhD As part of a clinical trial, Barbara received a two-step immunotherapy regimen. The first step consisted of a vaccine made from her own dendritic cells that were previously exposed to cancer cells from her tumor. These “smart” dendritic cells were then injected back into her lymph nodes where they help to stimulate her immune system to attack cancer cells in her body. In the second part of the immunotherapy, doctors removed T cells from her blood, grew them in billions of copies in the lab, and then re-infused them back into her body. The idea is that this army of T cells will be effective at eliminating cancer because they have been “educated” by the dendritic cell vaccine to recognize her cancer cells. This combined approach is designed to prevent recurrence of her ovarian cancer. Quote TigonTalker @TigonTalker · 2h Replying to @d_stock07734 It's really interesting when you explore all the #DCVax trials that Dr George Coukos has been involved with globally.

$NWBO in 1990 you could have bought DELL computer stock for .10 a share. $100 worth of stock was worth $5.2 million 10 years later. Think of how much NWBO Stock you own and let that sink in. Biggest thing to happen to cancer in 25 years!!!

$NWBO I wonder what time ex wannabe will show today to pollute the twits board today